|Title:||Oncogenic miR-137 contributes to cisplatin resistance via repressing CASP3 in lung adenocarcinoma||Authors:||Su, Te-Jen
Chen, Jeremy J. W.
|Keywords:||miR-137;lung adenocarcinoma;cisplatin;caspase 3;chemoresistance||Issue Date:||2016||Journal Volume:||6||Journal Issue:||6||Start page/Pages:||1317-1330||Source:||Am. J. Cancer Res.||Abstract:||
Although targeted therapy can prolong the survival of non-small cell lung cancer (NSCLC) patients with EGFR mutations, chemotherapy still is the choice for patients with wild-type EGFR or failure in targeted therapy. However, most of the patients will eventually develop chemoresistance. Our previous study showed that miR-137 is a risky microRNA and is associated with poor prognosis in NSCLC patients. Here we investigated the role of miR-137 in cisplatin resistance in lung adenocarcinoma patients. Our data indicated that miR-137 overexpression increases the survival of lung cancer cells exposed to cisplatin and decreases cisplatin-induced apoptosis. Through computational prediction and microarray, we identified caspase-3 (CASP3) as a potential target of miR-137. Luciferase reporter and site-directed mutagenesis assays demonstrated that miR-137 downregulates CASP3 through binding to its 3'-UTR. Moreover, the endogenous CASP3 can be modulated by overexpressing or silencing miR-137 in lung adenocarcinoma cell lines regardless of EGFR status. Suppression of CASP3 by miR-137 provides cancer cells with anti-apoptotic ability, leading to cisplatin resistance. Immunohistochemistry results revealed an inverse correlation between miR-137 and CASP3 expressions in lung adenocarcinoma patients. Together, our data provide a new chemoresistance mechanism in lung adenocarcinoma and a possible target to control chemoresistance in lung adenocarcinoma patients.
|Appears in Collections:||醫學檢驗暨生物技術學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.